On the basis of the previous studies between KRAS and Src, the potency of SKLB-178 against some KRAS mutant NSCLC cells, especially A549 (KRASG12S), may be mainly attributed to its inhibitory activity against Src kinase. This evidence concerns the gene SRC and non-small cell lung carcinoma.